The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins. |
Citations|
| US5015476 | Aug 11, 1989 | May 14, 1991 | Paravax, Inc. | Immunization implant and method | | US5340588 | Jan 23, 1992 | Aug 23, 1994 | Nova Pharmaceutical Corporation | Liposphere carriers of vaccines | | US5422109 | Feb 28, 1992 | Jun 6, 1995 | Societe d'Exploitation de Produits pour les Industries Chimiques (S.E.P.P.I.C.) | Fluid vaccines and active principle vehicles containing a metabolizable oil | | US5637300 | Aug 3, 1994 | Jun 10, 1997 | | Contraceptive vaccine comprising a glycosylated 55 kD zona pellucida protein immunogen and method of use of the same in contraception | | US5709879 | Jun 6, 1995 | Jan 20, 1998 | Chiron Corporation | Vaccine compositions containing liposomes | | US5736141 | Oct 30, 1996 | Apr 7, 1998 | Dalhousie University | Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant | | US5820879 | May 18, 1995 | Oct 13, 1998 | ACCESS Pharmaceuticals, Inc. | Method of delivering a lipid-coated condensed-phase microparticle composition | | US5897873 | Feb 23, 1995 | Apr 27, 1999 | The Liposome Company, Inc. | Affinity associated vaccine | | US5910306 | Nov 14, 1996 | Jun 8, 1999 | The United States of America as represented by the Secretary of the Army | Transdermal delivery system for antigen | | US5919480 | Jun 23, 1997 | Jul 6, 1999 | Yissum Research Development Company of the Hebrew University of Jerusalem | Liposomal influenza vaccine composition and method | | US5980898 | Jul 17, 1997 | Nov 9, 1999 | The United States of America as represented by the U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization | | US6090406 | Feb 26, 1990 | Jul 18, 2000 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants | | US6093406 | Feb 27, 1995 | Jul 25, 2000 | The United States of America as represented by the Secretary of the Army | Vaccine for induction of immunity to malaria | | US6110492 | May 28, 1998 | Aug 29, 2000 | Jenner Biotherapies, Inc. | Immunogenic compositions | | US6168804 | Sep 24, 1997 | Jan 2, 2001 | University of Alberta | Method for eliciting Th1-specific immune response | | US6309569 | May 13, 1999 | Oct 30, 2001 | Microbiological Research Authority | Encapsulation of bioactive agents | | US6406719 | Aug 3, 2001 | Jun 18, 2002 | Microbiological Research Authority | Encapsulation of bioactive agents | | US6534064 | Oct 10, 2000 | Mar 18, 2003 | Chiron Corporation | Stabilized protein particles for inducing cellular immune responses | | US6537966 | Jul 14, 2000 | Mar 25, 2003 | Human Genome Sciences, Inc. | Follistatin-3 | | US6565777 | May 29, 2002 | May 20, 2003 | Microbiological Research Authority | Encapsulation of bioactive agents | | US6670195 | May 26, 2000 | Dec 30, 2003 | New York University | Mutant genes in Familial British Dementia and Familial Danish Dementia | | USRE37224 | Jul 23, 1998 | Jun 12, 2001 | Dalhousie University | Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and adjuvant | | US20020110568 | Nov 6, 2001 | | | Vaccines with enhanced immune response and methods for their preparation |
Referenced by|
| US7344720 | Nov 15, 2004 | Mar 18, 2008 | Sanofi Pasteur SA | Vaccine composition | | US7824686 | Nov 20, 2008 | Nov 2, 2010 | Immunovaccine Technologies, Inc. | Vaccines with enhanced immune response and methods for their preparation |
Claims1. A vaccine composition, comprising: - (a) a carrier comprising a continuous phase of a hydrophobic substance;
- (b) liposomes;
- (c) an antigen encapsulated in said liposomes, said antigen being an antigen which, when not in said vaccine composition, has a conformation other than its native conformation, with the proviso that said antigen is other than a zona pellucida-derived antigen; and,
- (d) an adjuvant.
2. The composition of claim 1, wherein the hydrophobic substance is a liquid. 3. The composition of claim 2, wherein the carrier is an oil or a water-in-oil emulsion. 4. The composition of claim 3, wherein the oil is mineral oil, a vegetable oil or a nut oil. 5. The composition of claim 3, wherein the adjuvant is alum or another compound of aluminum. 6. The composition of claim 5, wherein the adjuvant is alum. 7. The composition of claim 3, wherein the antigen is a non-native, recombinant or denatured protein, a recombinant or synthetic peptide, or a fragment thereof. 8. The composition of claim 7, wherein the antigen is a viral, bacterial, protozoal or mammalian antigen. 9. The composition of claim 8, wherein the antigen elicits an antibody that recognizes a native epitope. 10. The composition of claim 9, wherein the native epitope is a mammalian epitope. 11. The composition of claim 10, wherein the mammal is a horse, a rabbit, a deer or a cat. 12. The composition of claim 7, wherein the antigen is alcohol dehydrogenase or a hepatitis B antigen. 13. The composition of claim 3, wherein the liposomes comprise unesterified cholesterol and a phospholipid with at least one head group selected from the group consisting of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine and phosphoinositol. 14. The composition of claim 3 which is essentially free of lipid A. |
